Search

We report the preparation and testing of a new alpha emitting radio-immunoconjugate (RIC) against acute myeloid leukaemia (AML) using CD33 positive monoclonal antibody WM-53 (specific for HL-60 cell line). Using cyclic anhydride of diethylenetriaminepentacetic acid (cDTPAa) as chelator, antibody was labeled with 213 Bi (alpha), 149 Tb (alpha), 153 Sm (beta) and 152 Tb (positron). In vitro testing showed high labeling efficiency (90–95%) and stability (11–19% leaching) with immunoreactivity virtually the same before and after labeling. DNA synthesis data and MTS cell survival were compared for all RICs. Only the alpha emitter was found to be capable of inhibiting DNA synthesis and had selective cell kill with activity as low as 2–3 μCi. The high stability and outstanding cytotoxicity of the 213 Bi conjugate provides the basis for targeted alpha therapy for the control of metastatic and disseminated cancer such as AML.

Amniotic fluid testosterone levels were measured by radioimmunoassay without chromatography on 101 specimens obtained at amniocenteses between 15 and 19 wk gestation. For the male fetus, the amniotic fluid testosterone level of 553 +/- 23 pmol/l (mean +/- SE) was significantly higher (P less than 0.0005) than the concentration found for the female fetus (206 +/- 9 pmol/l). There was an overlap of the ranges 74-1120 pmol/l for the male and 122-399 pmol/l for the female fetuses. Amniotic fluid testosterone levels above 400 pmol/l were observed in 84% of the male and in none of the female fetuses. The method allowed determination of testosterone levels within 8 h. It is concluded that amniotic fluid testosterone measured by radioimmunoassay without chromatography is a rapid and effective preliminary screening test for the prenatal diagnosis of fetal sex.